Abstract
Retrospective Single-Institution Analysis of Patients with Chronic Lymphocytic Leukemia with TP53 alterations Treated First-Line with Bruton's Tyrosine Kinase Inhibitor-Based Therapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have